Low-Dose Thalidomide Therapy for Refractory Cutaneous Lesions of LupusErythematosus
Open Access
- 1 January 2003
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 139 (1) , 50-54
- https://doi.org/10.1001/archderm.139.1.50
Abstract
CUTANEOUS manifestations of lupus erythematosus (LE) are chronic, disfiguring lesions that may be associated with systemic disease. These cutaneous lesions can be simply classified into 3 categories of lesions: (1) vascular lesions seen in systemic lupus erythematosus (SLE); (2) interface lesions seen in chronic cutaneous lupus erythematosus (CCLE), subacute cutaneous lupus erythematosus (SCLE), or SLE; or (3) special lesions as seen in LE profundus or in vesiculobullous lesions.1 There is potential for overlap between CCLE and SCLE, between CCLE and LE profundus, and between CCLE/SCLE and SLE.2Keywords
This publication has 20 references indexed in Scilit:
- Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patientsRheumatology, 1997
- Thalidomide Neuropathy Incidence and Clinicoelectrophysiologic Findings in 42 PatientsArchives of Dermatology, 1994
- Clinical, Histologic, and Immunofluorescent Distinctions Between Subacute Cutaneous Lupus Erythematosus and Discoid Lupus ErythematosusJournal of Investigative Dermatology, 1992
- Prevalence and expression of photosensitivity in systemic lupus erythematosus.Annals of the Rheumatic Diseases, 1989
- Annular subacute cutaneous lupus erythematosus responsive to dapsoneJournal of the American Academy of Dermatology, 1984
- Clofazimine in the treatment of annular lupus erythematosusArchives of Dermatology, 1981
- Serological Findings in Patients with “ANA-Negative” Systemic Lupus ErythematosusMedicine, 1981